Last Name


Search Results to Erin M. Guest

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following properties of Guest, Erin

research overview Dr. Guest's research areas of focus are in leukemia in infants, cancer genomics, and cancer predisposition syndromes. She is the study chair for the National Cancer Institute sponsored Children's Oncology Group clinical trial for infants with acute lymphoblastic leukemia (ALL) and she leads the national task force on infant ALL. Dr. Guest collaborates with researchers around the world to discover and develop new, more effective therapies for infants with leukemia.

One or more keywords matched the following items that are connected to Guest, Erin

Item TypeName
Concept Infant
Concept Infant, Newborn
Academic Article Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.
Academic Article Updates in the biology and therapy for infant acute lymphoblastic leukemia.
Academic Article Parental Perceptions of Obesity and Obesity Risk Associated With Childhood Acute Lymphoblastic Leukemia.
Academic Article Combined heparin/acid citrate dextrose solution A anticoagulation in the Optia continuous mononuclear cell protocol for pediatric lymphocyte apheresis.
Grant Identifying biomarkers of relapse in infant acute lymphoblastic leukemia (ALL) through single cell sequencing
Academic Article Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
Academic Article Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Grant A multi-omics approach to overcome resistance in infant leukemia by identifying immune-therapy failure mechanisms
Academic Article Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy.
Academic Article Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
Grant Next Generation Sequencing to Detect Minimal Residual Disease in Infant ALL
Academic Article Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia.
Grant Evaluating the Impact of Rare, Clinically Detected Germline Variants in MLL-AF4 Leukemia: A Bedside-to-Bench Translational Model of Infant ALL
Academic Article Outstanding outcomes in infants with KMT2A-germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial.
Academic Article Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia.
Academic Article Risk factors for cerebrospinal fluid shunt infections during an outbreak: a case-control study.
Academic Article Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Academic Article Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
Grant Venetoclax for infant ALL – COG AALL2321
Grant Refining risk stratification for infants with KMT2A-rearranged and KMT2A-germline B-ALL by immunoglobulin high-throughput sequencing analysis of patients enrolled on COG clinical trial AALL15P1

Search Criteria
  • Infant